Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It was another busy week for Australia's top brokers. This has led to the release of a number of broker notes.

Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:

Red buy button on an Apple keyboard with a finger on it.

Image source: Getty Images

Northern Star Resources Ltd (ASX: NST)

According to a note out of Goldman Sachs, its analysts have retained their buy rating on this gold miner's shares with a trimmed price target of $22.10. Goldman notes that Northern Star's production fell short of expectations during the third quarter due to the underperformance of the KCGM operation. However, while higher than consensus estimates, Goldman was pleased that its cash costs were broadly in line with its own estimates. Looking beyond this quarter, the broker remains very positive on the gold miner, highlighting its production growth as reasons to buy. Goldman points out that the expanded KCGM operations and other asset growth are taking group production toward ~2Mozpa from ~2027-29+ (and up to ~2.6Moz with the acquisition of De Grey Mining). The Northern Star share price ended the week at $19.17.

ResMed Inc. (ASX: RMD)

Another note out of Goldman Sachs reveals that its analysts have retained their conviction buy rating on this sleep disorder treatment company's shares with an improved price target of $49.30. This followed the release of ResMed's quarterly update late last month, which was broadly in line with Goldman's expectations. It notes that it was particularly pleased with the company's gross margin, which grew ~70bps sequentially and met the top end of management's guidance. Another positive was confirmation from the US Government that its medical devices are largely exempt from tariffs. All in all, Goldman remains very positive on the company and feels that its shares are undervalued at current levels. Especially given its forecast for earnings per share to grow at a compound annual growth rate of 17% between FY 2024 and FY 2027. The ResMed share price was fetching $37.26 at Friday's close.

Woolworths Group Ltd (ASX: WOW)

Analysts at Goldman Sachs have also retained their buy rating on this supermarket giant's shares with an increased price target of $36.50. According to the note, Goldman was pleased with Woolworths' performance during the third quarter. The broker points out that the company's sales were largely in line with estimates. This includes Australia Food sales being up 3.6% and comfortably ahead of industry growth rates for the period. Outside this, its analysts are expecting a strong recovery in both sales and earnings in FY 2026. So much so, Goldman is forecasting group sales growth of 4% and EBIT growth of 20% for the next financial year. As a result, it thinks the company's shares are good value at current levels. The Woolworths share price ended the week at $32.68.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Stressed shopper holding shopping bags.
Broker Notes

This retailer's dividend yield could top 8% in coming years: Broker

A strong profit result has set this company up for further growth.

Read more »

A woman studying share market stats on a computer while writing a report.
Broker Notes

Buy, hold, sell: SRG Global, Cochlear, NAB shares

As earnings season continues, Morgans has updated its ratings after scrutinising company reports.

Read more »

A young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Broker Notes

Buy, hold, sell: Car Group, Baby Bunting, Hub24 shares

We review three fresh buy, hold, and sell calls from expert market analysts. 

Read more »

Man working on his tablet with hologram of a world map and financial-related charts.
Broker Notes

Buy, hold, sell: Premier Investments, Hansen Technologies, Santos shares

Experts reveal their ratings on 3 ASX shares in the retail, energy, and technology segments. 

Read more »

Happy female accountant looking at her tablet.
Broker Notes

7 ASX 200 shares with reaffirmed buy ratings this week

Brokers retained a positive view on Santos, Zip, Coles, and other shares this week. 

Read more »

Broker working with share prices on computers.
Broker Notes

10 ASX 200 shares downgraded by analysts this week

Brokers reduced their ratings on QBE, Temple & Webster, BHP, and other stocks this week. 

Read more »

A woman in a red dress holding up a red graph.
Broker Notes

3 ASX stocks UBS rates as a buy after recent results

The broker is tipping these companies will continue to deliver.

Read more »

A wine technician in overalls holds a glass of red wine up to the light and studies it.
Broker Notes

Up 67%! Why the rebound in Treasury Wine shares may just be getting started

A leading analyst expects the big rebound in Treasury Wine shares is just the beginning.

Read more »